It appears that Relay Therapeutics has a shot at expanding the potential of its PI3Kα inhibitor beyond breast cancer. The company reported Tuesday that its candidate, called zovegalisib, delivered positive results in a Phase 2 trial in PIK3Cα-driven vascular anomalies. Ayisha Sharma has the details here.